Jefferson First Hospital in City to Offer New, Non-Invasive Tinnitus Treatment
The Jefferson Balance and Hearing Center of the Department of Otolaryngology – Head and Neck Surgery at Thomas Jefferson University Hospital is the first hospital in Philadelphia to offer the FDA-cleared Neuromonics Tinnitus Treatment. This therapy is proven to
interact, interrupt and desensitize tinnitus by delivering a customized neural stimulus, embedded in clinically modified music.
“Tinnitus is an awful, debilitating condition that can have a devastating impact on a patient’s quality of life,” said Thomas
Willcox, M.D., medical director. “This new treatment represents a significant step forward for a condition with traditionally
limited therapeutic options. By targeting underlying neurological and psychological causes, it has been proven to offer long-lasting
benefit.”
Tinnitus is the perception of sound in the ears or head when no external source is present. Often described as "ringing in
the ears," it affects as many as 50 million people in the United States. The Centers for Disease Control and Prevention report
that one million new cases of tinnitus are identified each year, 200,000 of which are severe. Tinnitus symptoms can negatively
impact normal daily activities and can lead to additional medical conditions, such as anxiety, depression, sleep deprivation
and elevated stress.
Tinnitus is not simply an auditory problem, but also has a neurological and psychological basis. While most tinnitus cases
are preceded by hearing loss, neurological factors often contribute to the deterioration in symptoms. First, the brain attempts
to compensate for the hearing loss by “turning up” sounds internally. Ultimately a psychological component emerges, when
the sufferer develops a “fight-or-flight” stress response to the debilitating sounds. The patient then focuses more attention
on the tinnitus, perceiving it as louder and louder. Tinnitus takes increasingly significant control over their life. Thus
begins a vicious cycle involving neurological, psychological and auditory factors.
Neuromonics’ non-invasive, FDA-cleared device is customized to the patient's unique hearing and tinnitus profile. It delivers
a customized neural stimulus that promotes neural plastic changes, allowing the brain to filter out thedisturbing tinnitus
sound. This stimulus is delivered within spectrally modified, customized music, which engages the brain's emotional response
center, the limbic system, and thereby reduces tinnitus-related disturbance.
The therapy is delivered via a compact, lightweight and uniquely designed medical device. Treatment typically occurs over
an approximately six-month period, with daily use recommended for two or more hours per day, especially when the tinnitus
is most disturbing. The treatment can take place during regular activities such as reading, relaxing or computer work. It
involves a multi-stage process designed for optimal clinical results.
Media Only Contact:Ed FedericoThomas Jefferson University Hospital
Phone: 215-955-6300
Published: 9-18-2009